OpenLB
Open Library of Bioscience
Advanced Search
Antibiotics (Basel, Switzerland)
Sep 22, 2020;9 (9):

Treatment of Bloodstream Infections Due to Gram-Negative Bacteria with Difficult-to-Treat Resistance.

Matteo Bassetti, Antonio Vena, Chiara Sepulcri, Daniele Roberto Giacobbe, Maddalena Peghin
Author Information
  1. Matteo Bassetti: Clinica Malattie Infettive, Ospedale Policlinico San Martino-IRCCS, 16132 Genoa, Italy.
  2. Antonio Vena: Clinica Malattie Infettive, Ospedale Policlinico San Martino-IRCCS, 16132 Genoa, Italy. ORCID
  3. Chiara Sepulcri: Clinica Malattie Infettive, Ospedale Policlinico San Martino-IRCCS, 16132 Genoa, Italy.
  4. Daniele Roberto Giacobbe: Clinica Malattie Infettive, Ospedale Policlinico San Martino-IRCCS, 16132 Genoa, Italy. ORCID
  5. Maddalena Peghin: Department of Medicine, Infectious Diseases Clinic, University of Udine and Azienda Sanitaria Universitaria Integrata, 33100 Udine, Italy.
PMID: 32971809 DOI: 10.3390/antibiotics9090632

Abstract

The rising incidence of Bloodstream Infections (BSI) due to Gram-Negative Bacteria (GNB) with difficult-to-treat resistance (DTR) has been recognized as a global emergency. The aim of this review is to provide a comprehensive assessment of the mechanisms of antibiotic resistance, epidemiology and treatment options for BSI caused by GNB with DTR, namely extended-spectrum Beta-lactamase-producing ; carbapenem-resistant ; DTR ; and DTR .

Keywords

Acinetobacter baumannii Enterobacteriales Gram-negative bacteria Pseudomonas aeruginosa difficult to treat bacteria

References

  1. Curr Opin Infect Dis. 2016 Dec;29(6):583-594 [PMID: 27584587]
  2. JAMA Surg. 2017 Mar 1;152(3):224-232 [PMID: 27851857]
  3. J Antimicrob Chemother. 2018 Jul 1;73(7):1872-1879 [PMID: 29659861]
  4. Clin Infect Dis. 2015 May 15;60(10):1462-71 [PMID: 25670823]
  5. Int J Antimicrob Agents. 2018 Aug;52(2):287-292 [PMID: 29654893]
  6. Trials. 2015 Jan 27;16:24 [PMID: 25623485]
  7. J Hosp Infect. 2015 Apr;89(4):241-7 [PMID: 25737092]
  8. J Antimicrob Chemother. 2017 Jan;72(1):268-272 [PMID: 27707990]
  9. Antimicrob Agents Chemother. 2018 Apr 26;62(5): [PMID: 29483119]
  10. Infect Drug Resist. 2019 Jul 01;12:1853-1867 [PMID: 31308706]
  11. Open Forum Infect Dis. 2019 Dec 12;6(12):ofz505 [PMID: 31858018]
  12. Clin Infect Dis. 2020 May 19;: [PMID: 32427286]
  13. Antibiotics (Basel). 2019 Mar 23;8(1): [PMID: 30909535]
  14. Antimicrob Agents Chemother. 2019 Sep 30;: [PMID: 31570403]
  15. Lancet Infect Dis. 2018 Dec;18(12):1319-1328 [PMID: 30509675]
  16. Antimicrob Agents Chemother. 2018 Jan 25;62(2): [PMID: 29158270]
  17. Expert Rev Clin Pharmacol. 2019 Nov;12(11):1037-1046 [PMID: 31607179]
  18. J Antimicrob Chemother. 2020 Jul 1;75(7):1840-1849 [PMID: 32277821]
  19. Expert Rev Anti Infect Ther. 2017 Jan;15(1):55-65 [PMID: 27766913]
  20. J Glob Antimicrob Resist. 2020 Sep;22:18-27 [PMID: 31863899]
  21. J Antimicrob Chemother. 2018 Oct 1;73(10):2782-2788 [PMID: 30010894]
  22. Clin Microbiol Infect. 2017 Oct;23(10):704-712 [PMID: 28893690]
  23. Future Microbiol. 2020 May;15:473-484 [PMID: 32301348]
  24. Int J Infect Dis. 2017 Sep;62:39-43 [PMID: 28610832]
  25. Antimicrob Agents Chemother. 2017 Oct 24;61(11): [PMID: 28848018]
  26. Int J Antimicrob Agents. 2019 Apr;53(4):456-466 [PMID: 30471402]
  27. N Engl J Med. 2019 Feb 21;380(8):791-793 [PMID: 30786196]
  28. Clin Infect Dis. 2019 May 17;68(11):1932-1934 [PMID: 30418554]
  29. Expert Rev Anti Infect Ther. 2020 Jul;18(7):643-655 [PMID: 32297801]
  30. Antimicrob Agents Chemother. 2020 Jan 27;64(2): [PMID: 31740559]
  31. Int J Antimicrob Agents. 2019 Dec;54(6):790-797 [PMID: 31284041]
  32. Clin Infect Dis. 2020 Jan 29;: [PMID: 31994704]
  33. Antimicrob Agents Chemother. 2018 Aug 27;62(9): [PMID: 29914962]
  34. Clin Infect Dis. 2006 Sep 1;43 Suppl 2:S49-56 [PMID: 16894515]
  35. Open Forum Infect Dis. 2020 Apr 21;7(5):ofaa139 [PMID: 32462046]
  36. N Engl J Med. 2019 Feb 21;380(8):729-740 [PMID: 30786187]
  37. Clin Microbiol Rev. 2020 May 13;33(3): [PMID: 32404435]
  38. Clin Microbiol Infect. 2012 Mar;18(3):268-81 [PMID: 21793988]
  39. Open Forum Infect Dis. 2020 May 21;7(6):ofaa185 [PMID: 32548207]
  40. Curr Opin Infect Dis. 2018 Dec;31(6):594-599 [PMID: 30299357]
  41. Open Forum Infect Dis. 2020 Jan 21;7(2):ofaa011 [PMID: 32042848]
  42. Clin Infect Dis. 2020 Apr 15;70(9):1799-1808 [PMID: 31400759]
  43. Biotechnol Adv. 2019 Jan - Feb;37(1):177-192 [PMID: 30500353]
  44. Clin Infect Dis. 2019 Jan 18;68(3):355-364 [PMID: 29893802]
  45. Expert Rev Anti Infect Ther. 2018 Apr;16(4):307-320 [PMID: 29493397]
  46. Chem Biol Drug Des. 2019 Aug;94(2):1427-1440 [PMID: 30925023]
  47. Antimicrob Agents Chemother. 2019 Jun 24;63(7): [PMID: 31085510]
  48. Clin Infect Dis. 2019 Aug 30;69(6):921-929 [PMID: 30561562]
  49. Clin Infect Dis. 2016 Dec 15;63(12):1615-1618 [PMID: 27624958]
  50. Int J Antimicrob Agents. 2019 Apr;53(4):520-524 [PMID: 30471403]
  51. J Antimicrob Chemother. 2017 Sep 1;72(9):2616-2626 [PMID: 28575389]
  52. J Antimicrob Chemother. 2018 Nov 1;73(11):3170-3175 [PMID: 30099490]
  53. Curr Opin Infect Dis. 2019 Dec;32(6):638-646 [PMID: 31577557]
  54. Sci Rep. 2019 Oct 29;9(1):15290 [PMID: 31664064]
  55. Intensive Care Med. 2020 Feb;46(2):266-284 [PMID: 32047941]
  56. Clin Infect Dis. 2019 Oct 15;69(9):1641-1642 [PMID: 30838418]
  57. Antibiotics (Basel). 2020 Feb 09;9(2): [PMID: 32050434]
  58. JAMA. 2018 Feb 27;319(8):788-799 [PMID: 29486041]
  59. Antimicrob Agents Chemother. 2017 Aug 24;61(9): [PMID: 28630191]
  60. Infection. 2019 Jun;47(3):363-375 [PMID: 30840201]
  61. Antimicrob Agents Chemother. 2015 Dec 14;60(3):1328-35 [PMID: 26666936]
  62. Antimicrob Agents Chemother. 2019 Aug 23;63(9): [PMID: 31262762]
  63. Int J Antimicrob Agents. 2020 Jul;56(1):105925 [PMID: 32084512]
  64. Open Forum Infect Dis. 2020 Feb 19;7(3):ofaa051 [PMID: 32161775]
  65. Antimicrob Agents Chemother. 2018 Oct 24;62(11): [PMID: 30104282]
  66. J Antimicrob Chemother. 2018 Oct 1;73(10):2777-2781 [PMID: 30010951]
  67. Antimicrob Agents Chemother. 2016 Sep 23;60(10):6234-43 [PMID: 27503659]
  68. Clin Infect Dis. 2018 Nov 28;67(12):1803-1814 [PMID: 30052813]
  69. Infect Drug Resist. 2019 Nov 21;12:3607-3623 [PMID: 31819544]
  70. J Antimicrob Chemother. 2016 Jul;71(7):2014-21 [PMID: 26994090]
  71. Intensive Care Med. 2012 Dec;38(12):1930-45 [PMID: 23011531]
  72. J Antimicrob Chemother. 2018 Apr 1;73(4):942-952 [PMID: 29272436]
  73. Int J Antimicrob Agents. 2019 Apr;53(4):408-415 [PMID: 30415002]
  74. Infect Dis Ther. 2018 Dec;7(4):439-455 [PMID: 30270406]
  75. Antimicrob Agents Chemother. 2017 Jul 25;61(8): [PMID: 28559250]
  76. Front Med (Lausanne). 2019 Apr 16;6:74 [PMID: 31041313]
  77. Clin Microbiol Rev. 2019 Nov 13;33(1): [PMID: 31722889]
  78. Clin Infect Dis. 2019 Sep 13;69(7):1091-1098 [PMID: 30535100]
  79. Ther Adv Infect Dis. 2020 May 14;7:2049936120912049 [PMID: 32489663]
  80. Lancet Infect Dis. 2019 Dec;19(12):1299-1311 [PMID: 31563344]
  81. Adv Ther. 2019 Jul;36(7):1771-1777 [PMID: 31098989]
  82. Pharmacotherapy. 2019 Nov;39(11):1113-1118 [PMID: 31550054]
  83. Clin Infect Dis. 2019 Nov 13;69(Suppl 7):S565-S575 [PMID: 31724043]
Journal Article Review
Article has an altmetric score of 1

Word Cloud

Created with Highcharts 10.0.0DTRbacteriaBSIGram-negativeGNBresistancerisingincidencebloodstreaminfectionsduedifficult-to-treatrecognizedglobalemergencyaimreviewprovidecomprehensiveassessmentmechanismsantibioticepidemiologytreatmentoptionscausednamelyextended-spectrumBeta-lactamase-producingcarbapenem-resistantTreatmentBloodstreamInfectionsDueGram-NegativeBacteriaDifficult-to-TreatResistanceAcinetobacterbaumanniiEnterobacterialesPseudomonasaeruginosadifficulttreat

Similar Articles

Cited By (32)